Diana Bytyqi, APRN
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,444 of the $52,619 with a category attached, or 76.9%. Novo Nordisk accounts for 61.6% of it on its own, with 34 other manufacturers making up the rest. 2025 is the largest year on record at $17,587, more than ten times the $452 reported in 2021. Among family clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 276 payments — averaging $190.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$32K
- Dexcom, Inc.$17K
- Lilly USA, LLC$436
- Amgen$394
- Boehringer Ingelheim$378
- Abbott$225
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$40,44477%
- Travel & lodging$5,78911%
- Food & beverage$6,20712%
- Education$1780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 65 | $32,414 |
| Dexcom, Inc. | 40 | $17,106 |
| Lilly USA, LLC | 25 | $436 |
| Amgen | 32 | $394 |
| Boehringer Ingelheim | 25 | $378 |
| Abbott | 12 | $225 |
| Xeris Pharmaceuticals, Inc. | 7 | $146 |
| Antares Pharma, Inc. | 5 | $135 |
| Medtronic | 6 | $124 |
| Amneal Pharmaceuticals LLC | 5 | $123 |
| Radius Health, Inc. | 5 | $119 |
| AbbVie | 5 | $104 |
| Bayer | 4 | $91 |
| Sanofi-aventis U.S. LLC | 5 | $91 |
| Cequr Corporation | 3 | $88 |
| Insulet Corporation | 3 | $69 |
| AstraZeneca | 4 | $68 |
| Kyowa Kirin, Inc. | 3 | $56 |
| Novartis | 2 | $53 |
| IBSA Pharma Inc. | 2 | $48 |
| Halozyme Inc | 2 | $45 |
| Merck | 2 | $42 |
| Tandem Diabetes Care, Inc. | 1 | $34 |
| Acella Pharmaceuticals, LLC | 2 | $31 |
| Clarus Therapeutics Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $20 |
| BETA Bionics, Inc. | 1 | $19 |
| Lifescan, Inc. | 1 | $19 |
| Mannkind Corporation | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $15 |
| Madrigal Pharmaceuticals | 1 | $14 |
| Averitas Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$16,481
- DEXCOM G7 GSS (161)$16,328
- RYBELSUS$10,355
- DEXCOM STELO GLUCOSE BIOSENSOR$6,617
How this compares
$52,619 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 400 | $478,574 |
| JardianceEmpagliflozin | 314 | $419,879 |
| OzempicSemaglutide | 286 | $402,871 |
| TrulicityDulaglutide | 97 | $148,137 |
| Tresiba Flextouch U-100Insulin Degludec | 130 | $77,671 |
| JanuviaSitagliptin Phosphate | 50 | $73,660 |
| FarxigaDapagliflozin Propanediol | 41 | $51,159 |
| Tresiba Flextouch U-200Insulin Degludec | 59 | $50,409 |
| TradjentaLinagliptin | 44 | $48,359 |
| RybelsusSemaglutide | 24 | $41,072 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $32,970 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $23,753 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 38 | $18,473 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $18,329 |
| Humalog Kwikpen U-100Insulin Lispro | 82 | $16,836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $436 | $632,775516 claims |
| Boehringer IngelheimJardiance, Tradjenta | $378 | $468,238358 claims |
| Novo NordiskOzempic, Rybelsus | $32,414 | $443,944310 claims |
| MerckJanuvia, Janumet, Janumet Xr | $42 | $107,40480 claims |
| AstraZenecaFarxiga | $68 | $51,15941 claims |
| AbbVieSynthroid | $104 | $8,23971 claims |
| IBSA Pharma Inc.Tirosint | $48 | $6,19323 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $123 | $2,084225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.
Other family in Derby
- Elisha ChristiansonWaterbury$371K
- Kathryn TierneyNew Britain$140K
- Jennifer SilvaSouth Windsor$91K
- Carli WillardEnfield$74K
- Erin MartinMilford$70K
- Dayna GiordanoNew Haven$65K
- Farhiya AbdiSouth Windsor$30K
- Nicole SandilandsBridgeport$30K
- Ralph HirschfeldPutnam$26K
- David OhotnickyTorrington$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.